Page 91 - The Flying Publisher Guide to Hepatitis C Treatment

References | 91

Belli L, Burroughs A, Burra P. Liver transplantation for HCV-cirrhosis: improved
survival in recent years and increased severity of recurrent disease in
female recipients: results of a longterm retrospective study. Liver Transpl
2007;13:733-40.
Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver
transplantation. J Hepatol 2001;35:666-78.
Berenguer M, Prieto M, Rayon JM, et al. Natural history of clinically compensated
HCV-related graft cirrhosis after liver transplantation. Hepatology
2000;32:852-8.
Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin
inhibitors with respect to the outcome of HCV recurrence after liver
transplantation: results of a meta-analysis. Liver Transpl 2007;13:21-9.
Berenguer M. Systematic review of the treatment of established recurrent
hepatitis C with pegylated interferon in combination with ribavirin. J
Hepatol 2008;49:274-87.
Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis
C virus genotype 1: comparing 48 versus 72 weeks of peginterferon alfa-2a
plus ribavirin. Gastroenterology 2006;130:1086-97.
Bode JG, Brenndörfer ED, Häussinger D. Hepatitis C virus (HCV) employs multiple
strategies to subvert the host innate antiviral response. Biol Chem
2008;389:1283-98.
Boursier J, de Ledinghen V, Zarski JP, et al. A new combination of blood test and
Fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in
chronic hepatitis C. Am J Gastroenterol 2011[Epub ahead of print]
Brillanti S, Vivarelli M, De Ruvo N, et al. Slowly tapering off steroids protects the
graft against hepatitis C recurrence after liver transplantation. Liver
Transpl 2002;8:884-8.
Brok J, Gluud LL, Gluud C. Meta-analysis: Ribavirin plus interferon vs. interferon
monotherapy for chronic hepatitis C–an updated Cochrane review. Aliment
Pharmacol Ther 2010;32:840-50.
Bruchfeld A, Lindahl K, Reichard O, et al. Pegylated interferon and ribavirin
treatment for hepatitis C in haemodialysed patients. J Viral Hepatitis 2006;
13:316-21.
Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to
interferon-alpha is associated with improved outcome in HCV-related
cirrhosis: a retrospective study. Hepatology 2007;45:579-87.
Cales P, Oberti F, Michalak S, et al. A novel panel of blood markers to assess the
degree of liver fibrosis. Hepatology 2005;42:1373-81.
Carrat F, Bani-Sadr F, Stanislas P, et al. Pegylated interferon alfa-2b vs. standard
interferon alfa-2b plus ribavirinfor chronic hepatitis C in HIV-infected
patients: a randomized controlled trial. JAMA 2004;292:2839-48.
Carrion J, Navasa M, Forns X. Retransplantation in patients with hepatitis C
recurrence after liver transplantation. J Hepatol 2010;53:962-70.
Chalasani N, Manzarbeitia C, Ferenci P, et al. Peginterferon alfa-2a for hepatitis C
after liver transplantation: two randomized, controlled trials. Hepatology
2005;41:289-98.